Business
Amarantus Provides Corporate Update
Amarantus Provides Corporate Update.
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\nNEW YORK, July 20, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink:AMBS) (the \"Company,\" or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today provided a business update on each of its subsidiaries Elto Pharma, Inc., Cutanogen Corporation, NeuroDx (pending formation to develop LymPro Test) and MANF Therapeutics, Inc. In addition, the Company provided guidance on its funding plan to complete its recapitalization and initiate its subsidiary spinoff plan.\n Elto Pharma The Elto Pharma project team (Drs. Trzepacz, Harvey and Brownell) has been focused on revising the Phase 2b eltoprazine clinical trial design and has now established a revised synopsis for a parallel design, Phase 2b Parkinson's disease levodopa-induced dyskinesia (PD-LID) trial that takes into account changes in the standard of care being made as a result of the recent approval of Adamas' Gocovri. The team is currently engaging with experts in the field ahead of regulatory interactions and expects to initiate the trial in the first half of 2019. In addition, there has been a renewed focus on evaluating a potential secondary indication for eltoprazine that is related to Alzheimer's disease. The team has made substantial progress, in consultation with our Alzheimer's SAB, in refining the target product profile for eltoprazine in that area. Further information on our plans in this area will be provided in the second half of 2018. Cutanogen The Cutanogen project team (Drs. Kagan, Ahrenholz, Harvey and Brownell) has been focused on defining the fastest path to market for Engineered Skin Substitute (ESS) in pediatric severe burns, and preparing to re-establish the ESS manufacturing process at a third-party cell therapy contract manufacturer. To this end, Cutanogen recently engaged with a new world-renowned cell therapy contract manufacturing organization (CMO) to assess and provide a roadmap to optimize the ESS manufacturing process in preparation for clinical trials expected to initiate in the first half of 2019. This effort will provide guidance on strategies to accelerate time to patient, reduce costs of good sold (COGS) and prepare to scale volume to meet the commercial need...